摘要：
2025年3月24日, 北京大学药学院天然药物及仿生药物全国重点实验室吕万良教授团队在著名学术期刊Nature Communications在线发表了题为“A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice“的研究工作。
Supporting:
北京大学药学院天然药物及仿生药物全国重点实验室. 吕万良团队发展了一种蛋白酶可裂解PD-L1抗体脂质体用于结肠癌免疫治疗[J]. 中国药学(英文版), 2025, 34(4): 407-407.
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. The research team of Prof. Wanliang Lu developed a protease-cleavable liposome for co-delivery of anti-PD-L1 for colon cancer therapy[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(4): 407-407.
>
>